Updated:
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA was founded in 1912 in Frankfurt as a pharmacy by Eduard Fresenius, later evolving into a publicly listed healthcare group...
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA was founded in 1912 in Frankfurt as a pharmacy by Eduard Fresenius, later evolving into a publicly listed healthcare group headquartered in Bad Homburg, Germany. The Else Kröner-Fresenius Foundation, a non-profit entity, holds the general partner stake, giving it decisive influence over strategic direction while separating commercial and philanthropic interests. This foundation structure, consolidated in 2011, is a defining governance feature — profits flow to medical research and humanitarian aid. The group operates through three main segments: Fresenius Medical Care, the world's largest provider of dialysis products and services with over 4,000 clinics globally; Fresenius Kabi, which makes generic IV drugs, clinical nutrition, and infusion pumps; and Fresenius Helios, the largest private hospital operator in Germany and a significant player in Spain. The firm generates approximately €40 billion in annual revenue from its mix of hospital services, dialysis care, and sterile pharmaceuticals. Operational reach spans more than 100 countries, with particular density in Europe, North America, and China. In October 2022, Michael Sen assumed the CEO role and immediately restructured the group to unwind the holding-company complexity that had eroded shareholder value. A landmark event came in December 2023 when Fresenius completed the deconsolidation of Fresenius Medical Care, converting it from a controlled subsidiary into an associate holding — a move designed to sharpen accountability and free capital for higher-return segments. The firm employs roughly 190,000 people worldwide and directed around €1.5 billion in capital expenditure toward expanding its Kabi and Helios divisions in the most recent fiscal year. The structural differentiator is governance, not market niche: the Else Kröner-Fresenius Foundation's role as a non-transferable general partner creates a permanent alignment with long-term healthcare outcomes. No other European healthcare conglomerate of this scale operates under a foundation model that blocks takeovers by statute and channels distributions to medical research — a buffer that allows management cycles to operate on a longer clock than quarterly investor demands.
General information
Firm type
other
Year founded
1912
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Bad Homburg
Corporate office
Else-Kröner-Straße 1, 61352 Bad Homburg, Germany
Principals
Michael Sen
Chairman of the Management Board (CEO)
Sector focus
Frequently asked questions
Who controls Fresenius, and how does the governance structure work?
The Else Kröner-Fresenius Foundation acts as the general partner of Fresenius SE & Co. KGaA, a legal form that grants it controlling influence over strategic decisions while the company remains publicly traded. The foundation was established from the estate of Else Kröner, who inherited the business and died in 1988, and it channels dividends into medical research and humanitarian projects. This structure makes a hostile takeover legally impossible and aligns corporate governance with multi-decade healthcare objectives rather than quarterly earnings. Michael Sen heads the Management Board under this foundation oversight.
How does Fresenius Medical Care relate to the parent company after the 2023 restructuring?
Fresenius Medical Care was deconsolidated from the Fresenius group in December 2023 and is now treated as an associate holding rather than a fully consolidated subsidiary. The parent company retains a 32% equity stake, but operational control and financial consolidation are now separated. The move was a centerpiece of Michael Sen's strategy to simplify a conglomerate structure that had weighed on the group's valuation. Investors had long criticized the complexity and capital allocation inefficiencies tied to the prior setup.
What is Fresenius Kabi's role in the group, and which markets does it serve?
Fresenius Kabi is the group's pharma and clinical-nutrition arm, specializing in generic IV drugs, infusion-therapy equipment, and enteral/parenteral nutrition products. It is a significant supplier to hospital systems globally, with a particular footprint in Europe, the United States, and China. Kabi competes directly with companies like B. Braun, Baxter, and ICU Medical. The division has been a capital-expenditure priority under Sen's restructuring, especially in expanding sterile manufacturing capacity.
Does the foundation's role affect Fresenius's ability to raise capital?
The Else Kröner-Fresenius Foundation's general-partner control provides governance stability but does not restrict the company from accessing equity or debt markets. Fresenius has issued bonds and maintained a DAX-listed public float for decades. The foundation's presence can be a credit-positive signal for long-term lenders, though some equity investors have historically applied a 'conglomerate discount' to shares. Sen's restructuring explicitly targeted that discount by simplifying the corporate structure.
What is the geographic split of Fresenius's hospital business?
Fresenius Helios is the largest private hospital operator in Germany, where it runs more than 80 hospitals and around 200 outpatient centers. It also owns Quirónsalud, the largest private hospital network in Spain, which it acquired in 2017 for €5.76 billion. The combined Helios/Quirónsalud platform generates the majority of the group's hospital revenue. Latin America is a smaller but growing footprint for the hospital division.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: